These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 12630290

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D, Helfrich B, Bunn PA.
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [Abstract] [Full Text] [Related]

  • 9. Protein kinase inhibitors as a therapeutic modality.
    Levitzki A.
    Acc Chem Res; 2003 Jun; 36(6):462-9. PubMed ID: 12809533
    [Abstract] [Full Text] [Related]

  • 10. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T, Gridelli C, Ciardiello F.
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [Abstract] [Full Text] [Related]

  • 11. Protein kinase inhibitors: insights into drug design from structure.
    Noble ME, Endicott JA, Johnson LN.
    Science; 2004 Mar 19; 303(5665):1800-5. PubMed ID: 15031492
    [Abstract] [Full Text] [Related]

  • 12. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
    Lage A, Crombet T, González G.
    Ann Med; 2003 Mar 19; 35(5):327-36. PubMed ID: 12952019
    [Abstract] [Full Text] [Related]

  • 13. Flavonoids as RTK inhibitors and potential anticancer agents.
    Teillet F, Boumendjel A, Boutonnat J, Ronot X.
    Med Res Rev; 2008 Sep 19; 28(5):715-45. PubMed ID: 18080331
    [Abstract] [Full Text] [Related]

  • 14. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, Weller M, Steinbach JP.
    Brain; 2009 Jun 19; 132(Pt 6):1509-22. PubMed ID: 19416948
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Novel combinations based on epidermal growth factor receptor inhibition.
    Adjei AA.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4446s-4450s. PubMed ID: 16857826
    [Abstract] [Full Text] [Related]

  • 17. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F, Lee HY.
    Drug Resist Updat; 2005 Oct 15; 8(5):298-310. PubMed ID: 16172017
    [Abstract] [Full Text] [Related]

  • 18. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
    Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM.
    Circulation; 2004 Mar 16; 109(10):1196-205. PubMed ID: 15023894
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.